Placebo News and Research

RSS

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan plc announced today the publication of the positive results of the Phase III trials of VIBERZITM C IV (eluxadoline) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in the January 21 issue of The New England Journal of Medicine.

21 Jan 2016

Mood disorder experts question effectiveness of metyrapone drug

Pioneering research by mood disorder experts at Newcastle University has questioned the effectiveness of metyrapone, a drug suggested to treat depression.

21 Jan 2016

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

OncoGenex Pharmaceuticals, Inc. announced today that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit.

20 Jan 2016

Traditional acupuncture no better than fake acupuncture for treating menopause symptoms

A new study has revealed traditional Chinese acupuncture treatments are no better than fake acupuncture for treating menopause symptoms.

20 Jan 2016

Higher levels of Omega-3 fatty acids could boost B vitamins' effect in preventing cognitive decline

While research has already established that B vitamin supplements can help slow mental decline in older people with memory problems, an international team have now found that having higher levels of Omega-3 fatty acids in your body could boost the B vitamins' effect.

20 Jan 2016

Stem cell transplantation of neurotrophic factors shows promise in ALS

Mesenchymal stem cells cultured to secrete neurotrophic factors can be administered to patients with amyotrophic lateral sclerosis without lasting unwanted effects and may have clinical benefits, indicates a phase I/II safety analysis study.

19 Jan 2016

Selexipag reduces clinical events in PAH patients

Selexipag, alone or in combination with other classes of pulmonary arterial hypertension medication, reduced the composite rate of disease complications and deaths among patients in a phase III trial.

19 Jan 2016

TG4010 vaccine promising in advanced NSCLC

Addition of the TG4010 vaccine to first-line chemotherapy improves outcomes in patients with advanced non-small-cell lung cancer, show the results of a placebo controlled trial.

19 Jan 2016

Citalopram of limited use for dementia-associated agitation

The use of citalopram for the treatment of agitation in Alzheimer’s disease may be limited to a small group of people with moderate agitation and low levels of cognitive impairment, study findings suggest.

19 Jan 2016

Anticholinesterase offers a ‘steadying hand’ to PD patients

The dementia drug rivastigmine may reduce the risk of falls in patients with Parkinson’s disease by improving gait stability, findings from the phase II ReSponD trial show.

19 Jan 2016

Profectus begins Phase 1 clinical study of VesiculoVax-vectored Ebola virus vaccine

Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the prevention and treatment of infectious diseases and the treatment of cancer, announced today the initiation of a Phase 1 clinical study of Profectus' VesiculoVax-vectored Ebola virus vaccine.

19 Jan 2016

New sites opened across the South West for Alzheimer’s disease clinical trial

People with Alzheimer’s disease are helping with a ground-breaking government-funded trial but with new sites recently opened in the South West more people are being asked to take part in the study led by academics from the Universities of Bristol, Cambridge, Queen’s University Belfast and University College London, and hosted by North Bristol NHS Trust.

19 Jan 2016

Specialized oral nutrition supplement associated with 50% lower death rate in older patients

Results from a new clinical trial show that a specialized oral nutrition supplement was associated with a 50 percent lower death rate in older malnourished patients with a heart or lung disease 90 days following hospitalization.

18 Jan 2016

Taking up new mental challenges may help maintain cognitive vitality

One of the greatest challenges associated with the growing numbers of aged adults is how to maintain a healthy aging mind. Taking up a new mental challenge such as digital photography or quilting may help maintain cognitive vitality, say researchers reporting in Restorative Neurology and Neuroscience.

18 Jan 2016

Oral drug rivastigmine could help prevent falls in people with Parkinson’s

Scientists have discovered that a commonly prescribed dementia drug could hold the key to helping prevent debilitating falls for people with Parkinson’s.

18 Jan 2016

Topiramate drug curbs marijuana use among young smokers, but with serious side effects

Combining the drug topiramate with psychological counseling curbed marijuana use among young smokers significantly more than did counseling alone, according to newly published results of a small randomized, controlled trial at Brown University. The results come with a caveat, however: many study volunteers couldn't tolerate the medicine's side effects.

18 Jan 2016

Large-scale clinical trial to evaluate dengue vaccine launched in Brazil

A large-scale clinical trial to evaluate whether a candidate vaccine can prevent the mosquito-borne illness dengue fever has been launched in Brazil. The vaccine, TV003, was developed by scientists in the laboratory of Stephen Whitehead, Ph.D., at NIH's National Institute of Allergy and Infectious Diseases (NIAID).

17 Jan 2016

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).

17 Jan 2016

JINARC (tolvaptan) accepted for use in Scotland for ADPKD treatment

From today, people in Scotland with the genetic kidney disease ADPKD could benefit from JINARC® (tolvaptan) following advice issued by the Scottish Medicines Consortium (SMC) for its use in adults with chronic kidney disease (CKD) stages 1-3 at the start of treatment with evidence of rapidly progressing disease.

12 Jan 2016

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

AbbVie, a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the safety and efficacy of its all-oral, once-daily, ribavirin-free investigational hepatitis C virus (HCV) regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, in patients with genotypes 1-6 (GT1-6) chronic HCV infection.

12 Jan 2016

Placebo News and Research

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Mood disorder experts question effectiveness of metyrapone drug

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

Traditional acupuncture no better than fake acupuncture for treating menopause symptoms

Higher levels of Omega-3 fatty acids could boost B vitamins' effect in preventing cognitive decline

Stem cell transplantation of neurotrophic factors shows promise in ALS

Selexipag reduces clinical events in PAH patients

TG4010 vaccine promising in advanced NSCLC

Citalopram of limited use for dementia-associated agitation

Anticholinesterase offers a ‘steadying hand’ to PD patients

Profectus begins Phase 1 clinical study of VesiculoVax-vectored Ebola virus vaccine

New sites opened across the South West for Alzheimer’s disease clinical trial

Specialized oral nutrition supplement associated with 50% lower death rate in older patients

Taking up new mental challenges may help maintain cognitive vitality

Oral drug rivastigmine could help prevent falls in people with Parkinson’s

Topiramate drug curbs marijuana use among young smokers, but with serious side effects

Large-scale clinical trial to evaluate dengue vaccine launched in Brazil

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

JINARC (tolvaptan) accepted for use in Scotland for ADPKD treatment

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News